Please login to the form below

Not currently logged in
Email:
Password:

China

This page shows the latest China news and features for those working in and with pharma, biotech and healthcare.

CAR-Ts take centre stage as ASH18 comes to a close

CAR-Ts take centre stage as ASH18 comes to a close

Back in the realm of ‘conventional’ CAR-T, China’s Legend Biotech posted encouraging data from a phase 1/2 trial of its Johnson &Johnson (J&J) partnered anti-BCMA therapy

Latest news

More from news
Approximately 84 fully matching, plus 478 partially matching documents found.

Latest Intelligence

  • Deal Watch October 2018

    Finally, Roche has done a second deal with the China‐based company Ark Biosciences, which specialises in developing treatments for respiratory diseases, this time for worldwide development and commercialisation rights to

  • The handover: Pfizer reshapes itself for a new era The handover: Pfizer reshapes itself for a new era

    This reflects the huge opportunity for growth in these products from China in particular. ... We need to make sure that we relocate the leadership to China where most of the growth is coming from.

  • Making Europe a leader in bioscience: boosting trust and opening minds Making Europe a leader in bioscience: boosting trust and opening minds

    to this revolution. These disruptions have reduced classic entry barriers, and the emergence of new big players like China has lowered the new barriers. ... Meanwhile, the emergence of China as an investor in innovation is set to transform the global

  • China: AstraZeneca’s new engine for growth and innovation China: AstraZeneca’s new engine for growth and innovation

    Mark Mallon is one of the chief architects of AstraZeneca’s current success in China. ... Digital health. So how important will innovations digital health going to be in China?

  • Chinese biotech’s global ambitions Chinese biotech’s global ambitions

    has just achieved a landmark approval in China for its own ‘home-grown’ cancer medicine. ... Nevertheless, Oyler observes that the sheer size of China means that there will be room for a number of leading oncology specialists, either multinationals

More from intelligence
Approximately 15 fully matching, plus 104 partially matching documents found.

Latest appointments

More from appointments
Approximately 2 fully matching, plus 34 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 10 fully matching, plus 54 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
bmore group

OUR PROMISE: BETTER HEALTH FROM TRIAL TO TREATMENT.We are a full service, independent network of specialist agencies under one roof....

Latest intelligence

Is China ready for a pharmaceutical gold rush?
Some describe doing business in China as akin to the 1990s internet boom – so how stable is its future?...
AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...

Infographics